Stem Cells Spin (WAR:SCS) NonCurrent Deferred Liabilities: zł0.00 Mil (As of Mar. 2026)


WAR:SCS Stem Cells Spin SA WAR:SCS
26 GF Score
Price zł0.37
GF Value zł0.10
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Stem Cells Spin NonCurrent Deferred Liabilities?

Stem Cells Spin WAR:SCS -6.50% 26 NonCurrent Deferred Liabilities is zł0.00 Mil as of Mar. 2026. GuruFocus rates WAR:SCS with a GF Score™ of 26/100 and a GF Value™ of zł0.10 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Stem Cells Spin's non-current deferred liabilities for the quarter that ended in Mar. 2026 was zł0.00 Mil.

Stem Cells Spin NonCurrent Deferred Liabilities Related Terms

Stem Cells Spin NonCurrent Deferred Liabilities Historical Data

* Premium members only.

The historical data trend for Stem Cells Spin's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Stem Cells Spin NonCurrent Deferred Liabilities Chart

Stem Cells Spin Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
NonCurrent Deferred Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Stem Cells Spin Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
WAR:SCS
26GF Score
Stem Cells Spin SA WAR:SCS
NonCurrent Deferred Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Liabilities of zł0.00 Mil mean?
Stem Cells Spin (WAR:SCS) has a NonCurrent Deferred Liabilities of zł0.00 Mil as of Mar. 2026. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Stem Cells Spin and its competitors.
Is Stem Cells Spin's NonCurrent Deferred Liabilities too high?
Stem Cells Spin's current NonCurrent Deferred Liabilities is zł0.00 Mil. Overall, Stem Cells Spin has a GF Score™ of 26/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Stem Cells Spin's NonCurrent Deferred Liabilities compare to VRTX and REGN?
Stem Cells Spin's NonCurrent Deferred Liabilities of zł0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Liabilities for a Biotechnology company?
A good NonCurrent Deferred Liabilities depends on the Biotechnology industry context. However, NonCurrent Deferred Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Liabilities mean?
A high NonCurrent Deferred Liabilities can signal that a stock is expensive relative to its fundamentals. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Stem Cells Spin and its competitors. Stem Cells Spin's current NonCurrent Deferred Liabilities is zł0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stem Cells Spin stock overvalued right now?
Based on GuruFocus' analysis, Stem Cells Spin (WAR:SCS) is currently considered Significantly Overvalued. The stock's GF Value™ is zł0.10, compared to a current price of zł0.37 — trading 274% above its estimated fair value. The current NonCurrent Deferred Liabilities is zł0.00 Mil. Stem Cells Spin's overall GF Score™ is 26/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Liabilities calculated?
NonCurrent Deferred Liabilities is calculated from a company's financial statements. For Stem Cells Spin (WAR:SCS), the current NonCurrent Deferred Liabilities is zł0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Stem Cells Spin (WAR:SCS) Overvalued in 2026?

Based on GuruFocus' analysis, Stem Cells Spin stock appears to be overvalued. The current stock price of zł0.37 is trading 274% above its estimated GF Value™ of zł0.10. GuruFocus considers Stem Cells Spin to be Significantly Overvalued.

Key valuation signals for WAR:SCS:

  • NonCurrent Deferred Liabilities: zł0.00 Mil
  • GF Value™: zł0.10 vs. price of zł0.37 (274% above fair value)
  • GF Score™: 26/100 with 3 warning signs

No single metric tells the full story. See the WAR:SCS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Stem Cells Spin Business Description

Address Ulica Konopnickiej 15 b, Wroclaw, POL, 51-141
Stem Cells Spin SA is a biotechnology company. The company is engaged in the development, production, marketing, and sale of natural regenerative products for the dermocosmetic and veterinary care markets, as well as applications for the human and veterinary medical industry. Its products include NHAC Biocervin MIC-1, Revitacell, PRS MIC-1, and Velvetyna.
26GF Score

Get the complete analysis for WAR:SCS

NonCurrent Deferred Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł0.37
Price
zł0.10
GF Value